CTI BioPharma | LinkedIn
Why CTI BioPharma Stock Crushed the Market Today | The Motley Fool
Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm'
CTI BioPharma | Targeted Blood Cancer Therapies | Home
CTI BioPharma | Targeted Blood Cancer Therapies | Home
CTI Biopharma surges 17% higher on Q3 earnings beat (NASDAQ:CTIC) | Seeking Alpha
CTI BioPharma | Targeted Blood Cancer Therapies | Home
CTI BioPharma: Q4, Missed Earnings, But Compelling Progress In Market Launch | Seeking Alpha
CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO
Stonepine Capital Management Cuts Stake in CTI BioPharma (CTIC) | Nasdaq
Cancers | Free Full-Text | Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?
CTI BioPharma | Compliance & Transparency
Struggling CTI reveals new pacritinib data, misses a primary endpoint | Fierce Biotech
CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial
Incyte's Jakafi Flunks In Phase III Myelofibrosis Study As Loss Of Exclusivity Nears :: Scrip
CTI BioPharma's PRE-VENT Trial Misses Endpoint In Severe COVID | Contract Pharma
CTI BioPharma | LinkedIn
CTI BioPharma and DRI Healthcare Trust Announce up to $135 Million Debt and Royalty Transaction
